Andere talen Dx & Vx Co., Ltd.

Aandelen

A180400

KR7180400004

slotkoers Korea S.E. Andere beurzen 00:00:00 27-06-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
2.450 ^KRW	-3,54%		-8,92%	-58,54%

2023	Dx&Vx ontwikkelt samen met LG CNS een bio-gezondheidszorg big data platform	CI
2023	Dx & Vx Co., Ltd. (KOSDAQ:A180400) voltooide de overname van 39,12% belang in Avixgen, Inc. van een groep verkopers	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Malaysian Genomics Resource Forge Strategic Alliance with South Korean Healthcare Solutions Provider	10/06
Dx&Vx Co-Develops Bio-Healthcare Big Data Platform with LG CNS	20/12
Dx & Vx Co., Ltd. completed the acquisition of Avixgen, Inc. from a group of sellers	28-06-23
Dx & Vx Co., Ltd. announced that it has received KRW 9.223311402 billion in funding from Renaissance Asset Management and other investors	14-06-23
Dx & Vx Co., Ltd. agreed to acquire Avixgen, Inc. from Renaissance Asset Management, Nouveau International Co., Ltd., Lee Mi-ja, Seo Jin - young, Kim Jae-hyun , Cho Il-hyun,Park So -yeon, Jeong Ja -woon, Kim Young- ju, Yang Young-jin, Kim Hye -min and Um In-kyung for KRW 9.2 billion.	24-05-23
DxVx Appoints Kevin Kwon as New President	16-05-23
DxVx Appoints Yong Gu Lee as CEO	16-05-23
Dx & Vx Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	13-04-23
Dx & Vx Co., Ltd. announced that it expects to receive KRW 9.223311402 billion in funding from Renaissance Asset Management and other investors.	07-04-23
Dx & Vx Co., Ltd. announced that it has received KRW 17 billion in funding	06-10-22
Dx & Vx Co., Ltd. completed the acquisition of Korea Biopharm Co., Ltd. from Jang, Byung Ha, Heo, Won Jung, Kim, Min E, Jang, So Yeon, Kim, Sung Gon and Hyun, Mi Ok.	04-10-22
Dx & Vx Co., Ltd. agreed to acquire Korea Biopharm Co., Ltd. from Jang, Byung Ha, Heo, Won Jung, Kim, Min E, Jang, So Yeon, Kim, Sung Gon and Hyun, Mi Ok for approximately KRW 15 billion.	15-09-22
Dx & Vx Co., Ltd. announced that it expects to receive KRW 1.78 billion in funding	07-09-22
Cancer Rop Co., Ltd. announced that it expects to receive KRW 20 billion in funding	30-08-21
Cancer Rop Co., Ltd. announced that it has received KRW 999.99252 million in funding	29-06-20
Cancer Rop Co., Ltd. announced that it expects to receive KRW 999.99252 million in funding	18-06-20
D S and partners limited company cancelled the acquisition of 10.2% stake in GI Innovation, Inc. from Cancer Rop Co., Ltd..	29-04-20
Cancer Rop Holdings Co., Ltd. cancelled the acquisition of 3.4% stake in Cancer Rop Co., Ltd. from Myungji Global Bio Fund.	11-07-19
Ds&Partners signed a contract to acquire 10.2% stake in GI Innovation, Inc. from Cancer Rop Co., Ltd. for KRW 7.5 billion.	29-04-19
Resort Savers, Inc. Announces Medical Distribution Partnership with South Korea based CancerROP	16-07-18

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Dx & Vx Co., Ltd.

Aandelen

A180400

KR7180400004

Andere talen

Filters